These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 22519397)

  • 1. Mechanisms involved in the protective effects of metformin against nonalcoholic fatty liver disease.
    Barbero-Becerra VJ; Santiago-Hernandez JJ; Villegas-Lopez FA; Mendez-Sanchez N; Uribe M; Chavez-Tapia NC
    Curr Med Chem; 2012; 19(18):2918-23. PubMed ID: 22519397
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.
    Forcheron F; Abdallah P; Basset A; del Carmine P; Haffar G; Beylot M
    Obesity (Silver Spring); 2009 Jul; 17(7):1381-9. PubMed ID: 19553925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Proteomic analysis of liver mitochondria of apolipoprotein E knockout mice treated with metformin.
    Stachowicz A; Suski M; Olszanecki R; Madej J; Okoń K; Korbut R
    J Proteomics; 2012 Dec; 77():167-75. PubMed ID: 22960565
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metformin increases hepatic leptin receptor and decreases steatosis in mice.
    Tang X; Li J; Xiang W; Cui Y; Xie B; Wang X; Xu Z; Gan L
    J Endocrinol; 2016 Aug; 230(2):227-37. PubMed ID: 27288055
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Metformin improves hepatic IRS2/PI3K/Akt signaling in insulin-resistant rats of NASH and cirrhosis.
    Xu H; Zhou Y; Liu Y; Ping J; Shou Q; Chen F; Ruo R
    J Endocrinol; 2016 May; 229(2):133-44. PubMed ID: 26941037
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of insulin-sensitizing agents in combination with ezetimibe, and valsartan in rats with non-alcoholic fatty liver disease.
    Assy N; Grozovski M; Bersudsky I; Szvalb S; Hussein O
    World J Gastroenterol; 2006 Jul; 12(27):4369-76. PubMed ID: 16865780
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Fetuin A in nonalcoholic fatty liver disease: in vivo and in vitro studies.
    Haukeland JW; Dahl TB; Yndestad A; Gladhaug IP; Løberg EM; Haaland T; Konopski Z; Wium C; Aasheim ET; Johansen OE; Aukrust P; Halvorsen B; Birkeland KI
    Eur J Endocrinol; 2012 Mar; 166(3):503-10. PubMed ID: 22170794
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current biochemical studies of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis suggest a new therapeutic approach.
    Hookman P; Barkin JS
    Am J Gastroenterol; 2003 Sep; 98(9):2093-7. PubMed ID: 14499793
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of metformin in the management of NAFLD.
    Mazza A; Fruci B; Garinis GA; Giuliano S; Malaguarnera R; Belfiore A
    Exp Diabetes Res; 2012; 2012():716404. PubMed ID: 22194737
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.
    Sofer E; Boaz M; Matas Z; Mashavi M; Shargorodsky M
    Metabolism; 2011 Sep; 60(9):1278-84. PubMed ID: 21411114
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Therapeutic effect of metformin and vitamin E versus prescriptive diet in obese adolescents with fatty liver.
    Akcam M; Boyaci A; Pirgon O; Kaya S; Uysal S; Dundar BN
    Int J Vitam Nutr Res; 2011 Nov; 81(6):398-406. PubMed ID: 22673924
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discordant effects on central obesity, hepatic insulin resistance, and alanine aminotransferase of low-dose metformin and thiazolidinedione combination therapy in patients with impaired glucose tolerance.
    Retnakaran R; Ye C; Hanley AJ; Harris SB; Zinman B
    Diabetes Obes Metab; 2012 Jan; 14(1):91-3. PubMed ID: 21812893
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Insulin sensitizer--anti-diabetic drugs, metformin and pioglitazone that can improve insulin resistance].
    Korenaga M; Kawaguchi K; Korenaga K; Uchida K; Sakaida I
    Nihon Rinsho; 2006 Jun; 64(6):1157-64. PubMed ID: 16768125
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Relation between augmentation index and adiponectin during one-year metformin treatment for nonalcoholic steatohepatosis: effects beyond glucose lowering?
    Shargorodsky M; Omelchenko E; Matas Z; Boaz M; Gavish D
    Cardiovasc Diabetol; 2012 Jun; 11():61. PubMed ID: 22676459
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
    Angelico F; Burattin M; Alessandri C; Del Ben M; Lirussi F
    Cochrane Database Syst Rev; 2007 Jan; (1):CD005166. PubMed ID: 17253544
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of action of metformin in nonalcoholic steatohepatitis.
    Mascitelli L; Pezzetta F; Goldstein MR
    Aliment Pharmacol Ther; 2009 Mar; 29(5):602-3; author reply 603-4. PubMed ID: 19183340
    [No Abstract]   [Full Text] [Related]  

  • 17. Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial.
    Haukeland JW; Konopski Z; Eggesbø HB; von Volkmann HL; Raschpichler G; Bjøro K; Haaland T; Løberg EM; Birkeland K
    Scand J Gastroenterol; 2009; 44(7):853-60. PubMed ID: 19811343
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapy of NAFLD: insulin sensitizing agents.
    Caldwell SH; Argo CK; Al-Osaimi AM
    J Clin Gastroenterol; 2006 Mar; 40 Suppl 1():S61-6. PubMed ID: 16540770
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic fatty liver disease and lipids.
    Wierzbicki AS; Oben J
    Curr Opin Lipidol; 2012 Aug; 23(4):345-52. PubMed ID: 22617751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of non-alcoholic fatty liver disease with metformin versus lifestyle intervention in insulin-resistant adolescents.
    Nadeau KJ; Ehlers LB; Zeitler PS; Love-Osborne K
    Pediatr Diabetes; 2009 Feb; 10(1):5-13. PubMed ID: 18721166
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.